Dishman Pharmaceuticals & Chemicals Ltd.[Merged] - Research Center
532526 DISHMAN Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 17 | Mar ' 16 | Mar ' 15 | Mar ' 14 | Mar ' 13 | |
|---|---|---|---|---|---|
| Sales | 451.49 | 510.39 | 478.69 | 473.28 | 484.64 |
| Operating profit | 148.13 | 170.78 | 149.25 | 176.21 | 167.55 |
| Interest | 39.17 | 68.66 | 68.13 | 69.22 | 51.10 |
| Gross profit | 179.76 | 164.50 | 148.12 | 162.97 | 130.04 |
| EPS (Rs) | 1.50 | 10.80 | 7.27 | 10.75 | 7.83 |
Annual
results in details
| Mar ' 17 | Mar ' 16 | Mar ' 15 | Mar ' 14 | Mar ' 13 | |
|---|---|---|---|---|---|
| Other income | 70.80 | 62.38 | 67.00 | 55.98 | 13.59 |
| Stock adjustment | -10.48 | 8.86 | -22.69 | -8.49 | 3.31 |
| Raw material | 139.41 | 179.07 | 196.23 | 178.97 | 173.50 |
| Power and fuel | - | - | 31.67 | - | - |
| Employee expenses | 66.76 | 65.89 | 58.88 | 58.38 | 58.21 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 107.67 | 85.79 | 65.35 | 68.21 | 82.06 |
| Provisions made | - | - | - | - | - |
| Depreciation | 135.85 | 44.25 | 44.13 | 44.13 | 35.34 |
| Taxation | 19.67 | 33.10 | 45.35 | 32.05 | 31.52 |
| Net profit / loss | 24.24 | 87.15 | 58.64 | 86.79 | 63.18 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 32.28 | 16.14 | 16.14 | 16.14 | 16.14 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | 311.49 | 311.11 | 311.77 |
| Agg.of non promotoholding (%) | - | - | 38.60 | 38.55 | 38.63 |
| OPM (%) | 32.81 | 33.46 | 31.18 | 37.23 | 34.57 |
| GPM (%) | 34.42 | 28.72 | 27.14 | 30.79 | 26.10 |
| NPM (%) | 4.64 | 15.22 | 10.75 | 16.40 | 12.68 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis